Novocure Stock Revenue
| NVCR Stock | USD 17.09 0.23 1.36% |
Novocure fundamentals help investors to digest information that contributes to Novocure's financial success or failures. It also enables traders to predict the movement of Novocure Stock. The fundamental analysis module provides a way to measure Novocure's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novocure stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 509.3 M | 299.5 M |
Novocure | Revenue |
Novocure Company Revenue Analysis
Novocure's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Novocure Revenue | 509.34 M |
Most of Novocure's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novocure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Novocure
Projected quarterly revenue analysis of Novocure provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Novocure match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Novocure's stock price.
Novocure Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Novocure is extremely important. It helps to project a fair market value of Novocure Stock properly, considering its historical fundamentals such as Revenue. Since Novocure's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novocure's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novocure's interrelated accounts and indicators.
| 0.99 | 0.95 | -0.79 | 0.98 | 0.77 | ||
| 0.99 | 0.98 | -0.83 | 0.97 | 0.82 | ||
| 0.95 | 0.98 | -0.87 | 0.96 | 0.89 | ||
| -0.79 | -0.83 | -0.87 | -0.84 | -0.92 | ||
| 0.98 | 0.97 | 0.96 | -0.84 | 0.85 | ||
| 0.77 | 0.82 | 0.89 | -0.92 | 0.85 |
Click cells to compare fundamentals
Novocure Revenue Historical Pattern
Today, most investors in Novocure Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novocure's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novocure revenue as a starting point in their analysis.
Novocure Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Novocure Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Novocure reported 509.34 M of revenue. This is 93.32% lower than that of the Health Care Equipment & Supplies sector and 72.26% lower than that of the Health Care industry. The revenue for all United States stocks is 94.6% higher than that of the company.
Novocure Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novocure's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novocure could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics of similar companies.Novocure is currently under evaluation in revenue category among its peers.
Novocure Current Valuation Drivers
We derive many important indicators used in calculating different scores of Novocure from analyzing Novocure's financial statements. These drivers represent accounts that assess Novocure's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Novocure's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 8.2B | 17.5B | 7.8B | 7.7B | 1.6B | 1.5B | |
| Enterprise Value | 8.2B | 17.7B | 8.1B | 8.1B | 1.9B | 1.8B |
Novocure ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novocure's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novocure's managers, analysts, and investors.Environmental | Governance | Social |
Novocure Institutional Holders
Institutional Holdings refers to the ownership stake in Novocure that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novocure's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novocure's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Two Sigma Advisers, Llc | 2024-06-30 | 1.3 M | Two Sigma Investments Llc | 2024-06-30 | 1.2 M | Millennium Management Llc | 2024-06-30 | 1.2 M | Voloridge Investment Management, Llc | 2024-06-30 | 1.1 M | Federated Hermes Inc | 2024-09-30 | 997.4 K | Northern Trust Corp | 2024-09-30 | 923.5 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 908 K | Frontier Capital Management Co Inc | 2024-09-30 | 871.4 K | Fmr Inc | 2024-09-30 | 16.2 M | Blackrock Inc | 2024-06-30 | 12.1 M |
Novocure Fundamentals
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.0793 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 1.56 B | ||||
| Shares Outstanding | 108.2 M | ||||
| Shares Owned By Insiders | 9.25 % | ||||
| Shares Owned By Institutions | 86.64 % | ||||
| Number Of Shares Shorted | 5.96 M | ||||
| Price To Earning | 721.15 X | ||||
| Price To Book | 5.13 X | ||||
| Price To Sales | 3.20 X | ||||
| Revenue | 509.34 M | ||||
| Gross Profit | 423.58 M | ||||
| EBITDA | (175.87 M) | ||||
| Net Income | (207.04 M) | ||||
| Cash And Equivalents | 948.52 M | ||||
| Cash Per Share | 9.06 X | ||||
| Total Debt | 596.24 M | ||||
| Debt To Equity | 1.31 % | ||||
| Current Ratio | 8.08 X | ||||
| Book Value Per Share | 3.34 X | ||||
| Cash Flow From Operations | (73.34 M) | ||||
| Short Ratio | 4.79 X | ||||
| Earnings Per Share | (1.39) X | ||||
| Price To Earnings To Growth | (0.47) X | ||||
| Target Price | 26.71 | ||||
| Number Of Employees | 1.45 K | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 1.85 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (985.5 M) | ||||
| Working Capital | 855.29 M | ||||
| Current Asset | 293.9 M | ||||
| Current Liabilities | 28.63 M | ||||
| Net Asset | 1.15 B |
About Novocure Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novocure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novocure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novocure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.